RedHill Biopharma annual gross margin
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
RedHill Biopharma Gross Margin Growth & History (RDHL)
RedHill Biopharma's gross margin was 60.31% for fiscal 2024.
View full RedHill Biopharma company overviewRedHill Biopharma annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | 60.31% | +13.28 pp |
| 2023 | 2023-12-31 | 47.03% | +0.97 pp |
| 2022 | 2022-12-31 | 46.06% | +3.67 pp |
| 2021 | 2021-12-31 | 42.39% | −0.29 pp |
| 2020 | 2020-12-31 | 42.68% | −21.41 pp |
| 2019 | 2019-12-31 | 64.09% | −1.97 pp |
| 2018 | 2018-12-31 | 66.06% | +19.12 pp |
| 2017 | 2017-12-31 | 46.94% | −53.06 pp |
| 2016 | 2016-12-31 | 100.00% | 0.00 pp |
| 2015 | 2015-12-31 | 100.00% | — |
RedHill Biopharma quarterly gross margin
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2022 | 2022-06-30 | 50.97% | +0.22 pp |
| Q2 2021 | 2021-06-30 | 50.75% | +18.64 pp |
| Q2 2020 | 2020-06-30 | 32.11% | −40.70 pp |
| Q2 2019 | 2019-06-30 | 72.81% | +3.66 pp |
| Q2 2018 | 2018-06-30 | 69.15% | +25.46 pp |
| Q2 2017 | 2017-06-30 | 43.69% | — |
RedHill Biopharma gross margin trends
Over the last five fiscal years, RedHill Biopharma's gross margin decreased from 64.09% to 60.31%, a change of −3.78 percentage points. The latest reported quarter, Q2 2022, shows 50.97%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RedHill Biopharma source filings ↗Community posts
RedHill reports wider first-half loss amid commercial-portfolio transition
RedHill Biopharma ($RDHL) reported a first-half net loss of $6.1 million, compared with $4.1 million a year earlier, and no revenue from continuing operations. Operating cash use was $4.6 million, while the half-year cash balance stood at $ ...
